Gammanorm Quality of Life Study in Immunodeficient Patients Using Rapid Push or Pumps
Launched by OCTAPHARMA · Jul 1, 2014
Trial Information
Current as of September 14, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult patients (≥ 18 years)
- • Presenting with primary immunodeficiency
- • Having received subcutaneous injections of immunoglobulin at home using an automatic pump for at least 1 month at the time of inclusion
- • For whom the investigator decides to maintain immunoglobulin replacement therapy with subcutaneous injections of Gammanorm® 165 mg/mL at home
- • Having signed an informed consent form
- Exclusion Criteria:
- • Patient currently participating in another interventional study at the time of inclusion
About Octapharma
Octapharma is a leading global pharmaceutical company specializing in the development and production of human proteins derived from human plasma and recombinant technologies. With a strong commitment to innovation and patient care, Octapharma focuses on creating high-quality therapeutic solutions for various medical conditions, including hematology, immunotherapy, and critical care. The company's extensive research and development efforts are complemented by a robust clinical trial program, aimed at advancing treatment options and improving patient outcomes worldwide. Driven by a dedication to excellence and a collaborative approach, Octapharma continues to make significant contributions to the healthcare industry.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tours, France
Lyon, France
Lille, France
Toulouse, France
Bordeaux, France
Caen, France
Limoges, France
Reims, France
Patients applied
Trial Officials
Boris Bienvenu, MD
Principal Investigator
Universtiy Hospital of Caen
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials